The numbers behind the Purdue Pharma’s settlement

Purdue Pharma, the maker of OxyContin, will dissolve and transform into a new public interest company as a landmark settlement takes effect Friday, marking a pivotal moment in America’s decades-long opioid crisis.

The settlement resolves thousands of lawsuits against the company and represents one of the largest agreements in a series of legal actions targeting those deemed responsible for the nation’s devastating opioid epidemic. Many observers have linked the aggressive marketing of OxyContin, a powerful prescription painkiller introduced in 1996, to the origins of the crisis that has claimed hundreds of thousands of American lives.

Since 1999, more than 900,000 Americans have died from opioid overdoses, according to federal data. The trajectory of the epidemic evolved from primarily prescription opioid deaths to heroin and, most recently, the highly potent synthetic opioid fentanyl, which has driven fatality rates to unprecedented levels.

The settlement provides a minimum of $7.4 billion in compensation, with at least $6.5 billion coming directly from members of the Sackler family who owned Purdue Pharma. As part of the agreement, the Sacklers have relinquished all ownership interests in the company, which they had already stopped controlling prior to its 2019 bankruptcy filing.

Purdue will now be replaced by Knoa Pharma, a new entity with a board appointed by states and an explicit mission to combat the opioid epidemic. On Friday, officials announced the three-member board of trustees for the foundation that will own Knoa: Rahul Gupta, former director of the White House Office of National Drug Control Policy under President Biden; Paul Rothman, previously CEO of Johns Hopkins School of Medicine; and David Saltzman, co-founder of the anti-poverty organization The Robin Hood Foundation.

The Purdue settlement adds to an estimated $57.8 billion in total opioid lawsuit settlements since 2019, according to the Opioid Settlement Tracker. These agreements have encompassed various players in the pharmaceutical supply chain, including drug manufacturers, wholesale distributors, pharmacy chains, and consulting firms. Settlement terms typically require that funds be directed specifically toward addiction treatment, prevention, and recovery services.

The payments from the Purdue settlement will be distributed over 15 years, with larger amounts coming in the early years to provide immediate resources for communities battling addiction crises. Notably, despite a Department of Justice investigation into Purdue that resulted in a corporate guilty plea, no individual executives or family members were criminally charged.

The path to this settlement faced significant hurdles, including a 2024 U.S. Supreme Court decision rejecting an earlier version of the agreement. Five of the nine justices ruled that Sackler family members could not receive personal liability protection through Purdue’s corporate bankruptcy process. The final agreement was revised to allow groups that decline settlement payments to retain their right to sue family members directly.

Financial records revealed in a 2019 audit showed that Sackler family members received $10.7 billion in distributions from Purdue between 2008 and 2018, with nearly half that amount going toward taxes the Sacklers paid on behalf of the company. No further distributions have occurred since then. A 2021 congressional committee report estimated the family’s total net worth at approximately $11 billion.

The settlement includes provisions for transparency, requiring the release of 30 million company documents. These will be maintained by the University of California San Francisco and Johns Hopkins University, joining other opioid industry documents that have become available through litigation.

Unlike other industry settlements, the Purdue agreement includes a mechanism for individual compensation. People who can demonstrate harm from prescribed Purdue opioids—or their survivors—may receive payments up to approximately $16,000 per claim.

As this settlement takes effect, communities across America continue to grapple with an opioid crisis that has evolved but shows little sign of abating, particularly as fentanyl continues to drive overdose deaths to record levels in many regions.